摘要
目的研究肾透明细胞癌组织中驱动蛋白超家族成员4A(kinesin family member 4A,KIF4A)的表达及其与临床病理因素和预后之间的关系。方法采用免疫组织化学染色方法检测145例肾透明细胞癌组织和配对60例癌旁正常肾组织中KIF4A的表达情况,比较KIF4A在肾透明细胞癌组织和癌旁正常肾组织中的阳性表达率,分析KIF4A的表达与肾透明细胞癌患者各临床病理因素及生存预后之间的关系。结果KIF4A在肾透明细胞癌组织中阳性表达率明显高于癌旁正常肾组织(31.7%vs.8.3%,P<0.01)。KIF4A的表达程度与肿瘤大小、淋巴结转移、远处转移和TNM分期有关(P<0.05),而与性别、年龄及T分期无关(P>0.05)。Kaplan-Meier生存分析的Log-rank检验显示KIF4A表达程度、肿瘤大小、T分期、淋巴结转移、远处转移及TNM分期与患者术后总生存时间相关,差异有统计学意义(P<0.01)。Cox回归分析显示KIF4A表达程度、远处转移及TNM分期均为影响肾透明细胞癌患者术后总生存时间的独立危险因素。结论KIF4A在肾透明细胞癌组织中表达明显高于癌旁正常肾组织,且与肾透明细胞癌发生转移进展相关,KIF4A有望成为判断肾透明细胞癌患者术后预后的参考指标。
Objective To investigate the expression of kinesin family member 4A(KIF4A)in clear-cell renal cell carcinoma(ccRCC)tissues and its relationship with clinicopathological features and prognosis.Methods The expression of KIF4A in 145 cases ccRCC and 60 matched cases of normal renal tissues adjacent to ccRCC were detected by immunohistochemistry.The positive expression rate of KIF4A in ccRCC and normal renal tissues adjacent to ccRCC was compared,and the relationship between KIF4A expression and clinicopathological factors and prognosis of patients with ccRCC was also analyzed.Results The positive rate of KIF4A expression in ccRCC tissues was significantly higher than that in adjacent normal renal tissues(31.7%vs.8.3%,P<0.01).The expression of KIF4A was correlated with tumor size,lymph node metastasis,distant metastasis and TNM stage(P<0.05),but not with gender,age and T stage(P>0.05).The Log-rank test of Kaplan-Meier survival analysis showed that the expression level of KIF4A,tumor size,T stage,lymph node metastasis,distant metastasis and TNM stage were correlated with the total survival time of the patients(P<0.01).Cox regression analysis showed that the expression of KIF4A,distant metastasis and TNM stage were independent risk factors for the total survival time of patients with ccRCC.Conclusions The expression of KIF4A in ccRCC is significantly higher than that in adjacent normal renal tissues,and it is related to the occurrence and metastasis of ccRCC.KIF4A is expected to be a reference index to judge the prognosis of patients with ccRCC.
作者
陆亚纯
付媛
白津
李连涛
刘桂红
LU Yachun;FU Yuan;BAI Jin;LI Liantao;LIU Guihong(School of Clinical Medicine,Xuzhou Medical University,Xuzhou,Jiangsu 221004,China;Jiangsu Key Laboratory of Biological Cancer Therapy,Xuzhou,Jiangsu 221002;School of Medical Imaging,Xuzhou Medical University,Xuzhou,Jiangsu 221004;Department of Radiation Oncology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221131)
出处
《徐州医科大学学报》
CAS
2020年第3期163-169,共7页
Journal of Xuzhou Medical University
基金
国家自然科学基金(81672845)。
